Christof von Eiff

机构：Pfizer (United States), Pfizer (Germany) · ORCID：0000-0002-7821-2359

发表论文 233 篇 · 总被引 16698 次 · h-index 67

代表论文

Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Germany (2024 · Expert Review of Vaccines · 被引 19)
Incidence of RSV-related hospitalizations for ARIs, including CAP: Data from the German prospective ThEpiCAP study (2025 · Journal of Infection · 被引 11)
Estimated Incidence Rate of Specific Types of Cardiovascular and Respiratory Hospitalizations Attributable to Respiratory Syncytial Virus Among Adults in Germany Between 2015 and 2019 (2025 · Influenza and Other Respiratory Viruses · 被引 5)
P-681. Estimated Incidence of Respiratory Syncytial Virus (RSV)-related Hospitalizations for Acute Respiratory Infections (ARIs), including Community Acquired Pneumonia (CAP), in Adults in Germany (2025 · Open Forum Infectious Diseases · 被引 2)
Incidence of all-cause and vaccine-preventable, radiologically confirmed community-acquired pneumonia in hospitalised adults in Germany: a multicentre surveillance study (2021–2023) (2026 · BMJ Open · 被引 1)
RSV Monitoring in Germany: A Critical Overview of Available Surveillance Systems (2025 · Journal of Clinical Medicine · 被引 1)